Contineum Therapeutics Statistics
Total Valuation
CTNM has a market cap or net worth of $322.17 million. The enterprise value is $145.26 million.
Important Dates
The last earnings date was Thursday, October 30, 2025, after market close.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CTNM has 29.18 million shares outstanding. The number of shares has increased by 96.27% in one year.
| Current Share Class | 23.10M |
| Shares Outstanding | 29.18M |
| Shares Change (YoY) | +96.27% |
| Shares Change (QoQ) | +8.57% |
| Owned by Insiders (%) | 1.79% |
| Owned by Institutions (%) | 40.55% |
| Float | 16.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.79 |
| P/TBV Ratio | 1.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 29.07, with a Debt / Equity ratio of 0.03.
| Current Ratio | 29.07 |
| Quick Ratio | 28.68 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.40% and return on invested capital (ROIC) is -21.42%.
| Return on Equity (ROE) | -30.40% |
| Return on Assets (ROA) | -20.89% |
| Return on Invested Capital (ROIC) | -21.42% |
| Return on Capital Employed (ROCE) | -36.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.45M |
| Employee Count | 41 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.87% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -21.87% |
| 50-Day Moving Average | 11.23 |
| 200-Day Moving Average | 7.52 |
| Relative Strength Index (RSI) | 49.95 |
| Average Volume (20 Days) | 172,584 |
Short Selling Information
The latest short interest is 1.19 million, so 4.08% of the outstanding shares have been sold short.
| Short Interest | 1.19M |
| Short Previous Month | 1.22M |
| Short % of Shares Out | 4.08% |
| Short % of Float | 7.14% |
| Short Ratio (days to cover) | 11.40 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -67.99M |
| Pretax Income | -59.39M |
| Net Income | -59.39M |
| EBITDA | -67.68M |
| EBIT | -67.99M |
| Earnings Per Share (EPS) | -$2.25 |
Full Income Statement Balance Sheet
The company has $182.41 million in cash and $5.49 million in debt, giving a net cash position of $176.91 million or $6.06 per share.
| Cash & Cash Equivalents | 182.41M |
| Total Debt | 5.49M |
| Net Cash | 176.91M |
| Net Cash Per Share | $6.06 |
| Equity (Book Value) | 180.47M |
| Book Value Per Share | 6.18 |
| Working Capital | 178.57M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$52.47 million and capital expenditures -$355,000, giving a free cash flow of -$52.83 million.
| Operating Cash Flow | -52.47M |
| Capital Expenditures | -355,000 |
| Free Cash Flow | -52.83M |
| FCF Per Share | -$1.81 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |